logo
Plus   Neg
Share
Email

AstraZeneca To Sell Rights To Seroquel, Seroquel XR In The US, Canada

AstraZeneca (AZN.L) has agreed to sell the commercial rights to Seroquel and Seroquel XR, used to treat schizophrenia and bipolar disorder, in the US and Canada to Cheplapharm Arzneimittel GmbH. Cheplapharm will make an upfront payment of $35 million to AstraZeneca and may also make future sales-contingent payments of up to $6 million.

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas. Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>